MYCENAX BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.4 TWD | +0.22% |
|
+11.00% | +29.97% |
| Sales 2022 | 732M 22.5M | Sales 2023 | 653M 20.06M | Capitalization | 7.35B 226M |
|---|---|---|---|---|---|
| Net income 2022 | -454M -13.95M | Net income 2023 | -683M -20.99M | EV / Sales 2022 | 9.99 x |
| Net cash position 2022 | 384M 11.79M | Net Debt 2023 | 58.59M 1.8M | EV / Sales 2023 | 11.4 x |
| P/E ratio 2022 |
-13.7
x | P/E ratio 2023 |
-10.7
x | Employees | 387 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 47.51% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.22% | ||
| 1 week | +11.00% | ||
| Current month | +20.36% | ||
| 1 month | +24.73% | ||
| 3 months | +21.47% | ||
| 6 months | +34.10% | ||
| Current year | +29.97% |
1 week
42.25
50.30
1 month
37.1550.30
Current year
34.9050.30
1 year
33.8550.80
3 years
31.6055.00
5 years
12.5071.40
10 years
12.5080.60
| Managers | Title | Age | Since |
|---|---|---|---|
Pei Chun Chen
CEO | Chief Executive Officer | - | 19-02-28 |
Wan Tzu Chang
DFI | Director of Finance/CFO | - | 19-04-07 |
Wei Yi Chou
CTO | Chief Tech/Sci/R&D Officer | - | 19-05-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kuo Pin Kao
BRD | Director/Board Member | - | 13-03-27 |
Wan Lai Cheng
BRD | Director/Board Member | - | 11-05-17 |
Sandy Lee
BRD | Director/Board Member | - | 19-08-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 46.4 | +0.22% | 11 181 470 |
| 24-04-22 | 46.3 | +4.04% | 4,514,442 |
| 24-04-19 | 44.5 | -0.89% | 2,819,997 |
| 24-04-18 | 44.9 | +1.58% | 2,491,865 |
| 24-04-17 | 44.2 | +5.36% | 3,822,334 |
End-of-day quote Taipei Exchange, April 22, 2024
More quotes
Mycenax Biotech Inc. is a Taiwan-based company principally engaged in the development and manufacture of pharmaceutical products. Its products are derived from mammalian cell culture and microbial fermentation. Its products include TuNEX, LusiNEX, GranNEX and AiNEX. Its products are applied in treatment of brain cancer, psoriasis and renal cell carcinoma, among others. The Company is also engaged in the provision of chemical, manufacturing and control (CMC) technology and the operation of a current good manufacture practice (cGMP) biopharmaceutical factory. The Company mainly operates its products within domestic market and to overseas markets.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +29.97% | 292M | |
| -0.49% | 103B | |
| +3.31% | 96.73B | |
| +1.66% | 21.31B | |
| -16.16% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.87% | 13.68B | |
| +6.32% | 13.44B | |
| +21.46% | 10.98B |
- Stock Market
- Equities
- 4726 Stock
